对高维度治疗的因果效应估计方法:放射疗法模拟研究研究
Alexander Jenkins1, Eliana Vasquez Osorio2,3, Andrew Green4
1Department of Electrical and Electronic Engineering, Imperial College London, London, UK.
Medical physics
|June 3, 2025
概括
使用新型因果适应拉索 (CAL) 估计器改善了放射治疗治疗结果,该估计器利用稀疏的因果推断. 与传统的基于voxel的方法相比,这种方法显著减少了偏差和平均平方误差.
科学领域:
- 医学物理 医学物理
- 辐射疗法 辐射疗法
- 因果推理因果推理
背景情况:
- 由于连续性,空间和混因素,放射治疗治疗结果分析是复杂的.
- 现有的基于voxel的估计器可能会产生偏差的结果,因为它们不使用因果推理框架.
研究的目的:
- 提出一种新的因果适应拉索 (CAL) 估计器,使用珍珠因果框架内的稀疏性.
- 在放射治疗剂量结果分析中解决当前基于voxel的估计器的局限性.
主要方法:
- 在网格上模拟2D放射治疗治疗计划,包括有风险的器官和目标体积.
- 利用定向非循环图来建模因果关系和混因素.
- 将CAL与基于voxel的回归估计器进行比较,使用模拟的计划和输送剂量,评估平均平方误差 (MSE) 和偏差.
主要成果:
- CAL估计器显著优于基于voxel的估计器,在总MSE中实现了高达四个数量级的改善.
- CAL的偏差明显较低,特别是在没有剂量反应的地区.
- 与基于voxel的MSE相比,获得的MSE<1x10^2 ≈1x10^6.
结论:
- 稀缺的因果推断方法提高了剂量反应区域的识别,并改善了治疗效果的估计.
- 因果推断提供了一个强大的框架,以克服基于voxel的放射治疗分析固有的局限性.
- 将因果推理应用于临床数据可以为治疗并发症提供新的见解.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Causality in Epidemiology
920
Causality or causation is a fundamental concept in epidemiology, vital for understanding the relationships between various factors and health outcomes. Despite its importance, there's no single, universally accepted definition of causality within the discipline. Drawing from a systematic review, causality in epidemiology encompasses several definitions, including production, necessary and sufficient, sufficient-component, counterfactual, and probabilistic models. Each has its strengths and...
920
Kaplan-Meier Approach
281
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
281
Comparing the Survival Analysis of Two or More Groups
303
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
303
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Hazard Ratio
263
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
263


